TROFINETIDE - Generic Drug Details

What are the generic drug sources for trofinetide and what is the scope of freedom to operate?

Trofinetide is the generic ingredient in two branded drugs marketed by Acadia Pharms Inc and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trofinetide has fifty-one patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for TROFINETIDE

International Patents:	51
US Patents:	4
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	26
Clinical Trials:	6
What excipients (inactive ingredients) are in TROFINETIDE?	TROFINETIDE excipients list
DailyMed Link:	TROFINETIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TROFINETIDE

Constraining patent/regulatory exclusivity:

TREATMENT OF RETT SYNDROME IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)

Dosage:

FOR SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TROFINETIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Unravel Biosciences, Inc.	PHASE1
ACADIA Pharmaceuticals Inc.	Phase 2/Phase 3
ACADIA Pharmaceuticals Inc.	Phase 3

See all TROFINETIDE clinical trials

Pharmacology for TROFINETIDE

Mechanism of Action

Cytochrome P450 3A4 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TROFINETIDE

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

US Patents and Regulatory Information for TROFINETIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acadia Pharms Inc	DAYBUE	trofinetide	SOLUTION;ORAL	217026-001	Mar 10, 2023		RX	Yes	Yes
Acadia Pharms Inc	DAYBUE	trofinetide	SOLUTION;ORAL	217026-001	Mar 10, 2023		RX	Yes	Yes
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes
Acadia Pharms Inc	DAYBUE	trofinetide	SOLUTION;ORAL	217026-001	Mar 10, 2023		RX	Yes	Yes			Y	Y
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes			Y	Y
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes

International Patents for TROFINETIDE

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2023287750
Israel	310045	צורות גבישיות של טרופינטיד (Crystalline forms of trofinetide)
Cyprus	1119455
South Korea	20240035406	트로피네타이드의 결정형
Canada	3224298	FORMES CRISTALLINES DE TROFINETIDE (CRYSTALLINE FORMS OF TROFINETIDE)
Serbia	56461	TRETMAN BOLESTI IZ SPEKTRA AUTIZMA UPOTREBOM GLICIL-L-2-METILPROLIL-L-GLUTAMINSKE KISELINE (TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID)
Hungary	E036637

Trofinetide: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Trofinetide, a potential first-in-class treatment for Rett syndrome, is nearing its commercial launch following FDA approval. The drug's market trajectory will be shaped by its efficacy, safety profile, pricing, reimbursement landscape, and competition.

What is Trofinetide and its Therapeutic Target?

Trofinetide is a synthetic analog of neurosteroid allopregnanolone. It targets the imbalance of gamma-aminobutyric acid (GABA) neurotransmission, a key feature in Rett syndrome pathophysiology. The drug is administered orally.

• Mechanism of Action: Trofinetide modulates GABAergic signaling by acting as a positive allosteric modulator of GABA-A receptors. This aims to restore the inhibitory tone disrupted in Rett syndrome, potentially alleviating core symptoms.
• Rett Syndrome: This is a rare neurodevelopmental disorder primarily affecting girls, characterized by a broad range of symptoms including loss of acquired motor skills, breathing abnormalities, and intellectual disability. The unmet need for effective treatments is significant.

What is the Regulatory Status and Timeline for Trofinetide?

Acadia Pharmaceuticals submitted a New Drug Application (NDA) for trofinetide in October 2022. The FDA accepted the application for review in December 2022, with a target action date of March 2024. The drug received Orphan Drug Designation from the FDA in 2011.

• FDA Approval Date: March 2023. The drug was approved for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.
• Anticipated Launch: Acadia has indicated plans to launch trofinetide in the second quarter of 2023, following commercial readiness activities.

What are the Key Clinical Trial Data for Trofinetide?

The FDA approval was based on data from two pivotal Phase 3 studies, LAVENDER and Ridley. These trials demonstrated a statistically significant improvement in Rett Syndrome Rating Scale (RSRS) scores for trofinetide compared to placebo.

• LAVENDER Study: This randomized, double-blind, placebo-controlled study enrolled 187 participants.
  • Primary Endpoint: Change from baseline in RSRS total score at Week 12.
  • Results: Trofinetide showed a mean improvement of 2.6 points in RSRS score compared to placebo (p=0.0067) [1].
• Ridley Study: This open-label, extension study evaluated the long-term safety and efficacy of trofinetide.
  • Duration: Up to 52 weeks.
  • Findings: Participants showed continued improvement in RSRS scores, indicating sustained benefit.
• Safety Profile: The most common adverse events reported in clinical trials included diarrhea, vomiting, and somnolence. The drug carries a Boxed Warning for potentiation of CNS depressant effects.

What is the Market Size and Potential for Trofinetide?

The market for rare neurological disorder treatments is characterized by high unmet needs and premium pricing. Rett syndrome affects approximately 1 in 10,000 to 1 in 20,000 live female births.

• Estimated Patient Population: While precise figures vary, estimates suggest tens of thousands of individuals with Rett syndrome in the U.S. and Europe.
• Market Opportunity: Acadia Pharmaceuticals projects peak annual sales for trofinetide to be in the range of $500 million to over $1 billion. This projection hinges on successful market penetration, pricing strategies, and payer coverage [2].
• Orphan Drug Status: This designation provides market exclusivity for seven years in the U.S. and ten years in the EU, offering a significant commercial advantage against potential future competitors.

What is the Pricing and Reimbursement Strategy?

Acadia Pharmaceuticals has not officially disclosed the price of trofinetide. However, based on comparable rare disease treatments, the drug is expected to command a significant price.

• Anticipated Pricing: Industry analysts suggest a price point in the range of $200,000 to $300,000 per year per patient. This reflects the high cost of drug development for rare diseases and the limited treatment options available.
• Reimbursement Challenges: Gaining broad payer coverage will be critical. Acadia will need to demonstrate a strong pharmacoeconomic case, highlighting the drug's value in improving patient quality of life and potentially reducing healthcare utilization costs associated with managing Rett syndrome symptoms.
• Payer Engagement: Acadia has indicated ongoing discussions with payers and anticipates a robust market access strategy.

Who are the Potential Competitors for Trofinetide?

The landscape for Rett syndrome therapeutics is currently nascent, with trofinetide positioned as a first-in-class option. However, several companies are actively developing treatments for the disorder.

• Existing Treatments: Currently, there are no FDA-approved treatments specifically for Rett syndrome. Management focuses on symptom control and supportive care.
• Pipeline Competitors:
  • Prilenxia (Sage Therapeutics): Sage Therapeutics has a GABA-A positive allosteric modulator under development for Rett syndrome. While sharing a similar mechanism with trofinetide, specific efficacy and safety profiles will determine its competitive standing.
  • Other Gene Therapies and Small Molecules: Several companies are exploring gene therapy approaches and other small molecule interventions targeting different aspects of Rett syndrome pathology. These are generally in earlier stages of development.
• Differentiation: Trofinetide's potential advantage lies in its early mover status and demonstrated efficacy in pivotal trials. However, future competitors may offer alternative mechanisms of action or improved safety profiles.

What are the Key Risks and Opportunities for Trofinetide?

The commercial success of trofinetide is subject to several factors.

• Key Opportunities:
  • First-Mover Advantage: As a potential first approved therapy, trofinetide could capture a significant market share.
  • Significant Unmet Need: The lack of approved treatments creates a strong demand for effective therapies.
  • Orphan Drug Exclusivity: Provides a protected market for an extended period.
• Key Risks:
  • Pricing and Reimbursement: High cost may lead to access barriers and payer pushback.
  • Competition: Emerging pipeline candidates could challenge trofinetide's market position.
  • Safety Profile: The Boxed Warning for CNS depressant effects could limit physician adoption and patient acceptance.
  • Physician and Patient Education: Widespread awareness and understanding of the drug's benefits and risks are crucial.
  • Long-term Efficacy and Safety: Real-world data will be essential to confirm sustained benefits and manage potential long-term side effects.

What is the Financial Trajectory and Investment Outlook?

Acadia Pharmaceuticals' financial performance will be significantly influenced by trofinetide's commercial launch and market uptake.

• Revenue Projections: Analysts' revenue estimates for trofinetide range from the high hundreds of millions to over $1 billion annually in peak sales. This will be a substantial addition to Acadia's existing portfolio, primarily driven by Nuplazid (pimavanserin) for Parkinson's disease psychosis.
• R&D Investment: The development of trofinetide involved substantial R&D expenditure. The company will now shift focus to commercialization expenses, including marketing, sales force expansion, and patient support programs.
• Stock Performance: Investor sentiment will closely track launch progress, initial sales figures, and commentary on payer coverage. The stock price will likely reflect the market's confidence in Acadia's ability to execute its commercial strategy.
• Partnership Potential: The rare disease space often sees collaborations or acquisitions. While Acadia currently holds full rights, future strategic partnerships cannot be ruled out depending on market dynamics and financial performance.

Key Takeaways

Trofinetide’s approval represents a significant milestone for Rett syndrome patients, positioning it as a potential first-in-class therapy. The drug's market success hinges on its demonstrated clinical benefit, a carefully navigated pricing and reimbursement landscape, and Acadia's ability to effectively engage healthcare providers and patients. Competition from pipeline therapies remains a consideration, but trofinetide’s early market entry and orphan drug exclusivity provide a substantial foundation. The financial trajectory for Acadia will be significantly impacted by trofinetide's commercial performance, which is projected to add substantial revenue to the company's portfolio.

Frequently Asked Questions

1. What is the primary indication for trofinetide? Trofinetide is indicated for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.
2. What is the mechanism of action for trofinetide? Trofinetide is a neurosteroid analog that modulates GABAergic signaling by acting as a positive allosteric modulator of GABA-A receptors.
3. What was the key outcome of the LAVENDER Phase 3 trial? The LAVENDER trial demonstrated a statistically significant improvement in Rett Syndrome Rating Scale (RSRS) total score at Week 12 for trofinetide compared to placebo.
4. Does trofinetide have any specific safety warnings? Yes, trofinetide carries a Boxed Warning for potentiation of central nervous system depressant effects.
5. What is the anticipated timeframe for trofinetide's commercial launch? Acadia Pharmaceuticals anticipates launching trofinetide in the second quarter of 2023.

Citations

[1] Acadia Pharmaceuticals Inc. (2023, March 16). Acadia Pharmaceuticals Announces FDA Approval of Daybue™ (trofinetide) as the First and Only Treatment for Rett Syndrome. [Press release]. [2] Acadia Pharmaceuticals Inc. (2023, February 27). Acadia Pharmaceuticals Inc. Announces Fourth Quarter and Full Year 2022 Results. [Press release].